top of page

Dragonfly News

Dragonfly's novel cytokines and TriNKET® NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.

May 21, 2024

Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors

Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors

DF9001 is currently being evaluated as a monotherapy for the treatment of Non-Small Cell Lung Cancer, Renal Cell Carcinoma and Head and...

December 5, 2023

Dragonfly Initiates Phase 1/1b Study of its IL-2 Immunotherapy

Dragonfly Initiates Phase 1/1b Study of its IL-2 Immunotherapy

The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh...

June 1, 2023

Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team

Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team

Six Dragonfly-developed drugs are presently in the clinic. WALTHAM, Mass., June 1, 2023 /PRNewswire/ -- Dragonfly Therapeutics, Inc.,...

February 2, 2023

Dr. Joseph E. Eid joins Dragonfly Therapeutics as President of R&D

Dr. Joseph E. Eid joins Dragonfly Therapeutics as President of R&D

Dr. Eid joins Dragonfly after 20 years of clinical development experience at Roche, Merck and BMS including as team leader at Merck in...

December 6, 2022

Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001

Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001

In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions...

April 21, 2022

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie

Dragonfly and AbbVie expand their existing collaboration in oncology and autoimmune disease to develop additional drug candidates in...

November 24, 2021

Merck and Dragonfly, Together Again

Merck and Dragonfly, Together Again

This morning, investors in privately-held Dragonfly Therapeutics are thankful after Merck opted to license its second TriNKET...

November 23, 2021

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly gets Merck on second TriNKET candidate since 2018 collab

Dragonfly Therapeutics is doing better and better in getting Big Pharma on its TriNKET platform. First Celgene, then BMS, and now Merck —...

March 5, 2024

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303

This is the eighth drug using Dragonfly's platform technology, and the sixth TriNKET® to enter into clinical trials. WALTHAM, Mass.,...

August 8, 2023

One R.I. man’s battle with Stage 4 colon cancer

One R.I. man’s battle with Stage 4 colon cancer

‘You’re going to die no matter what. So fight this thing and beat it.’ Five years ago, Ward Thrasher was diagnosed with Stage 4 colon...

April 17, 2023

Dragonfly Therapeutics Announces the Publication of Preclinical Data

Dragonfly Therapeutics Announces the Publication of Preclinical Data

Supporting DF6002, its Extended Half-life IL-12 Cytokine, as a Promising Treatment for Cancer The publication titled "An optimized...

January 6, 2023

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb

Today's announcement marks the first TriNKET opt-in outside of oncology. Dragonfly to receive a $25 million payment and is eligible to...

November 1, 2022

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target

Milestone payment to Dragonfly is triggered by dosing of first patient in Phase 1 clinical trial Dragonfly Therapeutics, Inc....

March 31, 2022

Dragonfly Therapeutics Expands Clinical Leadership Team

Dragonfly Therapeutics Expands Clinical Leadership Team

Appointing Dr. Hesham Aboshady as Head of Safety & Pharmacovigilance and Rajesh Israni as Head of Regulatory Affairs. Hesham Aboshady MD,...

November 24, 2021

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

Merck buzzes Dragonfly for 2nd immunotherapy candidate in $700M pact

The dragon is flying high today as Merck hits go on a second immunotherapy candidate from its $700 million pact with Dragonfly...

November 23, 2021

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Dragonfly Therapeutics Announces Merck Opt-In of TriNKET™ Immunotherapy Candidate for Patients

Merck executes option to license its second immunotherapy candidate from the companies' 2018 collaboration for solid tumor targets....

February 15, 2024

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications

Trodelvy and HER-2 TriNKET combinations will be in metastatic breast cancer (mBC) and non-small cell lung cancer (NSCLC). WALTHAM, Mass.,...

June 5, 2023

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results

Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results

In the ASCO Developmental Therapeutics – Immunotherapy Session, Dr. Howard Safran presents encouraging data on Dragonfly's phase 1/2...

February 6, 2023

Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine

Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine

Dragonfly now wholly owns the IL12 cytokine, currently in mid-Phase 1 dose escalation as a monotherapy and in combination with nivolumab....

December 8, 2022

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™

Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2. In its Phase 1 study DF1001 was...

May 2, 2022

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop NK Cell Engagers

Gilead and Dragonfly Announce Strategic Research Collaboration to Develop NK Cell Engagers

Gilead Sciences, Inc. (Nasdaq: GILD) and Dragonfly Therapeutics today announced a collaboration designed to advance a number of...

March 1, 2022

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat

Two years ago, Bristol Myers Squibb R&D boss Rupert Vessey unveiled one of the biggest cash deals he’d done, focusing on the high-risk,...

November 24, 2021

Merck hits 'go' on a second Dragonfly drug

Merck hits 'go' on a second Dragonfly drug

Merck & Co. Inc. has decided to move forward on its option to license a second drug from Waltham-based Dragonfly Therapeutics. The two...

November 9, 2021

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

Dragonfly Announces DF1001 Granted Orphan Drug Designation in the US for Esophageal Cancer

The company announces that its lead TriNKET™ immunotherapy program DF1001, a HER2-targeted NK cell engager therapy...

bottom of page